Thiazolidinediones News and Research

RSS

Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.

NDA for Exenatide once weekly accepted for FDA review

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA).

7 Jul 2009

Discovery of genetic markers to help fight diabetes

Translational Genomics Research Institute (TGen) scientists have identified five genetic biomarkers that could help lead to improved treatments, with fewer side-effects, for patients with diabetes.

17 Jun 2009

Diabetes drug pioglitazone shows potential against multiple sclerosis

A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report in a study currently available online in the Journal of Neuroimmunology.

26 May 2009

People with Ala12 gene variant need to watch out for high fat in their diets

New evidence in mice bolsters the notion that a version of a gene earlier shown to protect lean people against weight gain and insulin resistance can have the opposite effect in those who eat a high-fat diet and are heavier, reveals a report in the January 7th issue of the journal Cell Metabolism, a Cell Press publication.

6 Jan 2009

$Thiazolidinediones doubles risk of fractures in women$

Thiazolidinediones doubles risk of fractures in women

New findings out of Wake Forest University School of Medicine and the University of East Anglia show that long-term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes.

10 Dec 2008

New evidence shows that the heart beats to its own drummer

They've uncovered some of the molecular circuitry within the cardiovascular system itself that controls the daily rise and fall of blood pressure and heart rate. The findings might also explain why commonly used diabetes drugs come with cardiovascular benefits, according to the researchers.

3 Dec 2008

Risks associated with diabetes drug rosiglitazone may be higher than those with pioglitazone

Older adults who take the diabetes medication rosiglitazone appear to have a higher risk of death and heart failure than those taking the related medication pioglitazone, according to a report in the November 24 issue of Archives of Internal Medicine.

24 Nov 2008

FDA continues review of Takeda's NDA for Alogliptin

Takeda Pharmaceutical Company Limited has announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S. Food and Drug Administration (FDA) will not be able to complete its review of the alogliptin New Drug Application (NDA) by the Prescription Drug User Fee Act (PDUFA) date of October 27, 2008.

12 Oct 2008

Advances in the management of diabetes mellitus

The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.

1 Sep 2008

Thiazolidinediones - diabetes drugs carry significant cardiovascular risks

A class of oral drugs used to treat type 2 diabetes may significantly increase the risk of serious cardiovascular events, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members.

28 Aug 2008

Thiazolidinediones may slow bone formation and speed bone loss

A widely used class of diabetes medications appears to be associated with an increased risk for fractures, according to a report in the April 28 issue of Archives of Internal Medicine.

28 Apr 2008

Researchers discover molecular pathway in blood vessels that controls blood pressure and vascular function

University of Iowa researchers have identified a molecular pathway in blood vessels that controls blood pressure and vascular function and may help explain why certain drugs for type II diabetes also appear to lower patients' blood pressure.

6 Mar 2008

For safety, NHLBI changes intensive blood sugar treatment strategy in trial of diabetes and cardiovascular disease

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped one treatment within a large, ongoing North American clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns after review of available data, although the study will continue.

6 Feb 2008

New understanding of the link between heart disease and belly fat

By now, everyone knows that overweight people have a higher risk of heart attacks, strokes and other problems that arise from clogged, hardened arteries. And people who carry their extra weight around their waist - giving them a "beer belly" or an "apple" shape - have the highest risk of all.

22 Jan 2008

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.

7 Jan 2008

Use of thiazolidinediones by seniors linked with increased risk of heart problems

Older patients treated with the diabetes medications known as thiazolidinediones (which include rosiglitazone) had a significantly increased risk of heart attack, congestive heart failure and death, compared with the use of other hypoglycemic drugs, according to a study in the December 12 issue of JAMA.

13 Dec 2007

Study finds Avandia may increase risk of heart failure

A popular class of drugs for treating type 2 diabetes is under scrutiny again. A new Canadian study released by the Institute for Clinical Evaluative Sciences (ICES) finds that drugs such as Avandia increase the risk of heart failure, heart attacks and death.

13 Dec 2007

GlaxoSmithKline response to JAMA article on ICES retrospective analysis

The following is GlaxoSmithKline's response to the retrospective analysis by the Institute for Clinical Evaluative Sciences (ICES) titled "Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes".

13 Dec 2007

Rosiglitazone and Pioglitazone increase risk of congestive heart failure but not the risk of cardiovascular death

Patients with type 2 diabetes* or prediabetes* are more likely to develop congestive heart failure (CHF) when given rosiglitazone or pioglitazone, as compared with controls. However these drugs did not increase the risk of cardiovascular death (CVD) for these patients.

1 Oct 2007

Discovery may lead to new class of diabetes drugs

A multidisciplinary team led by researchers at the University of California, San Diego has determined the structure of a protein found in cells that shows potential as a target for the development of new drugs to treat diabetes.

30 Aug 2007

Thiazolidinediones News and Research

NDA for Exenatide once weekly accepted for FDA review

Discovery of genetic markers to help fight diabetes

Diabetes drug pioglitazone shows potential against multiple sclerosis

People with Ala12 gene variant need to watch out for high fat in their diets

Thiazolidinediones doubles risk of fractures in women

New evidence shows that the heart beats to its own drummer

Risks associated with diabetes drug rosiglitazone may be higher than those with pioglitazone

FDA continues review of Takeda's NDA for Alogliptin

Advances in the management of diabetes mellitus

Thiazolidinediones - diabetes drugs carry significant cardiovascular risks

Thiazolidinediones may slow bone formation and speed bone loss

Researchers discover molecular pathway in blood vessels that controls blood pressure and vascular function

For safety, NHLBI changes intensive blood sugar treatment strategy in trial of diabetes and cardiovascular disease

New understanding of the link between heart disease and belly fat

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Use of thiazolidinediones by seniors linked with increased risk of heart problems

Study finds Avandia may increase risk of heart failure

GlaxoSmithKline response to JAMA article on ICES retrospective analysis

Rosiglitazone and Pioglitazone increase risk of congestive heart failure but not the risk of cardiovascular death

Discovery may lead to new class of diabetes drugs

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Natural products: the next frontier in drug discovery

Latest News